Aytu BioPharma, Inc. (AYTU)
- Previous Close
1.1000 - Open
1.0600 - Bid --
- Ask --
- Day's Range
1.0500 - 1.1099 - 52 Week Range
0.9500 - 3.4500 - Volume
30,807 - Avg. Volume
34,785 - Market Cap (intraday)
6.849M - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0800 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
aytubio.com102
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: AYTU
View MorePerformance Overview: AYTU
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AYTU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AYTU
View MoreValuation Measures
Market Cap
6.85M
Enterprise Value
2.30M
Trailing P/E
--
Forward P/E
0.81
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.10
Price/Book (mrq)
0.22
Enterprise Value/Revenue
0.03
Enterprise Value/EBITDA
0.42
Financial Highlights
Profitability and Income Statement
Profit Margin
-6.79%
Return on Assets (ttm)
-2.51%
Return on Equity (ttm)
-22.74%
Revenue (ttm)
77.23M
Net Income Avi to Common (ttm)
-7.23M
Diluted EPS (ttm)
-2.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
20.4M
Total Debt/Equity (mrq)
55.71%
Levered Free Cash Flow (ttm)
9.05M